Abstract:Background. Immune checkpoint inhibitors (ICIs) have become a standard care in non-small-cell lung cancer (NSCLC). However, its application to epidermal growth factor receptor (EGFR)-mutant NSCLC patients is confronted with drug resistance. This study aimed to clarify the potential role of Yes1-associated transcriptional regulator (YAP1) in ICIs treatment for EGFR-mutant NSCLC population. Methods. All the clinical data of NSCLC were downloaded from Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) for GSE11969 and GSE72094. Based on YAP1 expression, all the NSCLC patients including the EGFR-mutant and EGFR-wildtype (WT) patients were divided into two groups, YAP1_High and YAP1_Low. Using cBioPortal, genetic alterations were analyzed for identification of immunogenicity in EGFR-mutant NSCLC. MR analysis was used to analyze the hub gene of EGFR. The infiltration of immune cells and the expression of the identified tumor-associated antigens were identified with TIMER. By graph learning-based dimensionality reduction analysis, the immune landscape was visualized. Moreover, survival analysis was performed to verify the predictive value of YAP1 in ICIs treatment for EGFR-mutant NSCLC population using Ren's research data (NCT03513666). Results. YAP1 was a poor prognostic factor of EGFR-mutant NSCLC population rather than lung adenocarcinoma (LUAD) patients. MR analysis revealed that the EGFR gene regulated YAP1 expression. YAP1 was identified as a hub gene closely associated with immunosuppressive microenvironment and poor prognosis in EGFR-mutant NSCLC population in TCGA LUAD. Tumors with YAP1_High showed an immune-"cold" and immunosuppressive phenotype, whereas those with YAP1_Low demonstrated an immune-"hot" and immunoactive phenotype. More importantly, it was verified that YAP1_High subpopulation had a significantly shorter progression-free survival (PFS) and overall survival (OS) after ICIs treatment in EGFR-mutant NSCLC patients in the clinical trial. Conclusions. YAP1 mediates immunosuppressive microenvironment and poor prognosis in EGFR-mutant NSCLC population. YAP1 is a novel negative biomarker of ICIs treatment in EGFR-mutant NSCLC population. Clinical Trials. This trial is registered with .

Effect of silencing of Yes-associated protein 1 gene on proliferation and invasion of human non-small cell lung cancer cells

Yes-associated protein modulation of human glioma cell growth invitro

Inhibitory effect of knocking-down Yes-associated protein for the growth of SNB19 glioma cells

Overexpression of Yes-Associated Protein Contributes to Progression and Poor Prognosis of Non-Small-cell Lung Cancer.

YAP1 Expression is Associated with Survival and Immunosuppression in Small Cell Lung Cancer

Generation of Yes-associated Protein 1 Short Hairpin RNA Plasmid and Its Effects on Proliferation， Migration and Invasion of Bladder Cancer T24 Cells

Expression of Yes-associated protein in non-small cell lung cancer and its relationship with clinical pathological factors.

MicroRNA-138 Acts As a Tumor Suppressor in Non Small Cell Lung Cancer Via Targeting YAP1

Overexpression Of Yes-Associated Protein Contributes To Apoptosis Of Lung Cancer

Silence Yes-associated Protein Expression Inhibit the Invasion Ability of Hepatocellular Carcinoma Cells

Yes-associated protein overexpression in colon cancer and association with SW480 cells proliferation and invasion

Targeted-knockdown of Yes-associated protein inhibits the Warburg effect and the invasion of laryngeal cancer cells

The Effects of Downregulation of YAP1 Gene Expression by Sirna on Malignant Biological Behavior of Pancreatic Cancer Cells

Influence of Yes-associated protein-1 on proliferation and metastasis of gallbladder carcinoma

Knockdown of Yes-Associated Protein Inhibits Proliferation and Downregulates Large Tumor Suppressor 1 Expression in MHCC97H Human Hepatocellular Carcinoma Cells

Effect of YAP Inhibition on Human Leukemia HL-60 Cells

Yes-Associated Protein 1 Promotes Adenocarcinoma Growth and Metastasis Through Activation of the Receptor Tyrosine Kinase Axl

LINC02159 promotes non-small cell lung cancer progression via ALYREF/YAP1 signaling

YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer

Yes-associated protein regulates the growth of human non-small cell lung cancer in response to matrix stiffness.

MiR-497 Suppresses YAP1 and Inhibits Tumor Growth in Non-Small Cell Lung Cancer